

Digitalis lanata Digoxin, BSA-Conjugated

DAG3043 *Digitalis lanata*

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview	Digitalis lanata Digoxin, BSA-Conjugated
Description	Digoxin BSA conjugate
Species	Digitalis lanata
Position	Digoxin-3
Conjugate	BSA
Form	Supplied in 0.015 M phosphate, 0.15 M NaCl, pH 7.2, 0.1% NaN ₃
Applications	immunoassay development or other applications.
Usage	For Research Use Only. Not intended for diagnostic use. Suitable for use in immunoassay development or other applications.

PACKAGING

Storage	Store at 2-8°C. short term and -20°C. long term
Concentration	1.0 mg/ml

BACKGROUND

Introduction	Digoxin is a purified cardiac glycoside extracted from the foxglove plant, <i>Digitalis lanata</i> . Its corresponding aglycone is digoxigenin, and its acetyl derivative is acetyldigoxin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade names Lanoxin, Digitek, and Lanoxicaps. It is also available as a 0.05 mg/ml oral solution and 0.25 mg/ml or 0.5 mg/ml injectable solution. It is marketed by GlaxoSmithKline and many other pharmaceutical manufacturers.
Keywords	Digoxin; Lanoxin; cardoxin; davoxin; digitalis; dilanacin; dokim; dynamos; lanatilin; lanoxicaps; neodioxanin; rougoxin; saroxin; oxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl(oxy); 14-dihydroxy-, (3beta,5beta,12beta)-xopyranosy

REFERENCES

1. Sticherling C, Oral H, Horrocks J et al. (November 2000). "Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness" (pdf). *Circulation* 102 (20): 2503–2508.
2. Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H (October 2007). "Digoxin and mortality in atrial fibrillation: a prospective cohort study". *European Journal of Clinical Pharmacology* 63 (10): 959–971.